^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    NR3C1 overexpression

    i
    Other names: NR3C1, Nuclear Receptor Subfamily 3 Group C Member 1, GR, Glucocorticoid Receptor, GRL, Nuclear Receptor Subfamily 3, Group C, Member 1 (Glucocorticoid Receptor), Nuclear Receptor Subfamily 3 Group C Member 1 Variant HGR-B(54), Nuclear Receptor Subfamily 3 Group C Member 1 Variant HGR-B(77), Nuclear Receptor Subfamily 3 Group C Member 1 Variant HGR-B(93), Nuclear Receptor Subfamily 3, Group C, Member 1, Glucocorticoid Nuclear Receptor Variant 1, GCRST, GCCR, GCR
    Entrez ID:
    2908
    28d
    Proteogenomic Landscape of Breast Ductal Carcinoma Reveals Tumor Progression Characteristics and Therapeutic Targets. (PubMed, Adv Sci (Weinh))
    In addition, AKR1C1 is identified as a potential therapeutic target and demonstrated the inhibitory effect of aspirin and dydrogesterone as its inhibitors on tumor cells. The integrative multi-omics analysis helps to understand the progression of BRDC and provides an opportunity to treat BRDC in different stages.
    Journal
    |
    ER (Estrogen receptor) • TP53 (Tumor protein P53) • AR (Androgen receptor) • AKR1C1 (Aldo-Keto Reductase Family 1 Member C1) • TIAM1 (TIAM Rac1 Associated GEF 1) • NR3C1 (Nuclear Receptor Subfamily 3 Group C Member 1)
    |
    TP53 mutation • NR3C1 overexpression
    |
    aspirin
    1year
    Prediction and prognostic potential of NR3C1 gene expression level in DLBCL patients. (PubMed, Hematology)
    In multivariate analysis, NR3C1 high expression was an independent prognostic factor that predicted a longer OS of DLBCL (OS, P = 0.0003). NR3C1 is considered an independent predictor of DLBCL patients and can be used as a biomarker for the prognosis of DLBCL.
    Journal
    |
    NR3C1 (Nuclear Receptor Subfamily 3 Group C Member 1)
    |
    NR3C1 overexpression
    |
    Rituxan (rituximab)
    over1year
    The expression of glucocorticoid and mineralocorticoid receptors in pituitary tumors causing Cushing's disease and silent corticotroph tumors. (PubMed, Front Endocrinol (Lausanne))
    Similar relationship between USP8 mutations and expression levels were observed in analysis of silent tumors that also revealed a negative correlation between GR and tumor size and higher NR3C1 expression in densely granulated tumors. Although the associations between gene/protein expression and patients clinical features are not strong, they consistently show an evident trend in which higher receptor expression corresponds to more favorable clinical characteristics.
    Journal
    |
    NR3C1 (Nuclear Receptor Subfamily 3 Group C Member 1)
    |
    NR3C1 overexpression